Connect with us
neuralink v0.9 device neuralink v0.9 device

News

EXCLUSIVE: Neuralink dragged into humane testing lawsuit – Timeline of Events

Elon Musk shows off the Neuralink v0.9 Device (Credit: Neuralink)

Published

on

Neuralink has been dragged into a lawsuit by the Physicians Committee for Responsible Medicine against the University of California at Davis. The lawsuit, which is amended from its initial filing date of May 2021, seeks to have UC Davis release images and video of inhumanely-treated test subjects, including monkeys, who died after participating in some trials of Neuralink-sponsored research for the development of neural interface implant devices. We have put together an exclusive timeline of events based on interviews and an examination of over 700 pages of documents that UC Davis was required to turn over to the PCRM.

The Physicians Committee for Responsible Medicine (PCRM) is a nonprofit organization with more than 17,000 doctor members. It filed a formal complaint with the United States Department of Agriculture today, claiming UC Davis and Neuralink staff violated the federal Animal Welfare Act related to experiments performed on 23 monkeys. Neuralink paid more than $1.4 million to UC Davis to carry out the experiments.

The PCRM said in a press release that Neuralink and the University “failed to provide dying monkeys with adequate veterinary care, used an unapproved substance known as “Bioglue” that killed monkeys by destroying portions of their brains, and failed to provide for the psychological well-being of monkeys assigned to the experiment.”

In an exclusive interview with Teslarati earlier today, Jeremy Beckham, MPA, MPH, PCRM’s Research Advocacy Coordinator, said that the lawsuit really intends to open up “basic facts about what Neuralink testing did to the animals.” Beckham said monkeys had their brains mutilated in the experiments. Veterinary records, which were shared with Teslarati by the PCRM, show that UC Davis and Neuralink staff performed invasive and deadly experiments on monkeys to assess the effectiveness of the Neuralink device. The letter sent from the PCRM to the USDA earlier today gives several graphic descriptions of how the test animals were treated.

Advertisement

RELATED:

Neuralink details humane animal treatment during Link v0.9 testing

One animal, known as “Animal 6,” was a 6-year-old macaque monkey who was killed on January 16, 2019. The letter states that, on October 10, 2018, implanted electrodes “were placed using an investigational robot,” then, “attached to skull using titanium implant screws.” The location of the screws began to become infected, according to the letter. By January 14th, “Animal 6” had started to pick at the infected area. Staff euthanized the monkey two days later.

Timeline of Events

PCRM has been working to clarify the situation since September 2020, but a more descriptive timeline of events would clarify how Neuralink, UC Davis, and the PCRM have all combined into this issue.

Advertisement
  • May 2017 – The University of California at Davis and Neuralink sign and agree to Non-Disclosure Agreements regarding testing.
  • September 2017 – UC Davis and Neuralink officially begin their collaboration to carry out primate experiments at UC Davis facilities. The goal is to develop a brain-machine interface.
  • July 2018 – “Animal 4,” an 11-year-old macaque monkey is killed in the Neuralink/UC Davis experiments, according to the complaint. The monkey was “on anti-depressants and had chronic diarrhea and poor appetite.” Additionally, the monkey was observed as “lethargic” and “depressed,” and hunched and passed bloody diarrhea. The monkey eventually died in a deadly procedure on July 20th.
    • Also in July 2018 – “Animal 12,” approximately 7-years-old, undergoes a craniotomy and electrode insertion procedure. Records show the animal had “severe clinical adverse effects following the implantation, had poor stool quality, was not eating, and had an eye infection.” Records abruptly ended on July 30th.
  • September 2018 – “Animal 21,” a 7-year-old female macaque undergoes an “electrode insertion survivability” procedure using “investigational robotics.” The animal was observed with adverse side effects the following day, including vomiting, gasping, retching, and had little interaction with their environment and observers. The animal was euthanized and had signs of “Bioglue,” an unapproved adhesive, covering the brain.
  • December 2018 – “Animal 15,” a 7-year-old female macaque undergoes a craniotomy and recording device implantation. Following the surgery, the area became infected and bloody. The animal was euthanized on March 21, 2019. The performed necropsy shows “remnant electrode threads.”
  • January 2019 – “Animal 6,” a 6-year-old macaque monkey is killed as a part of the “experimental design.” Electrodes were secured by screws drilled into the monkey’s skull, and lab staff were forced to “frequently clean” the eroding skin near the monkey’s implant site.
  • March 2019 – “Animal 11” is killed at approximately 11-years-old during a terminal procedure. The monkey had an implant placed on the head or brain on December 3rd, 2018, and began experiencing symptoms like a weakened appetite and missing fingers and toes, possibly caused by self-mutilation.
  • January 2020 – “Animal 5,” another macaque monkey is killed “inadvertently” by an anticonvulsant. He showed signs of significant weight loss and alopecia.
  • July 2020 – Neuralink’s Elon Musk announces that the company will hold an event on August 28th, 2020, to display the progress of the V0.9 device. “Will show neurons firing in real-time on August 28th. The matrix in the matrix,” Musk said in a Tweet.
    • Also in July 2020 – Neuralink receives a ‘breakthrough device’ designation from the FDA in July, and the company is working with the agency to make the technology as safe as possible.
  • August 2020 – Neuralink unveils the v0.9 device, displaying healthy and functioning pigs. Musk delivers a presentation on the new device, showing the simplified product Neuralink has developed. “It’s like a FitBit in your skull with tiny wires,” Musk half-joked. “I could have it right now and you wouldn’t even know. Maybe I do!” The device is said to be installed without general anesthesia. There will be no bleeding, and no noticeable damage after the device is implanted.
  • September 2020 – The PCRM files a California Public Records request, wishing for information regarding UC Davis trials of the Neuralink device. The request is eventually denied in accordance with California State Code 6255(a), which says that the Agency “shall justify withholding any record by demonstrating that the record in question is exempt under express provisions of this chapter or that on the facts of the particular case the public interest served by not disclosing the record clearly outweighs the public interest served by disclosure of the record.”
  • October 2020 – “Animal 10,” an 8-year-old macaque monkey, is shipped to Neuralink’s facility in Fremont. The monkey has significant hair loss, had lesions from “unspecified traumas,” and was exhibiting self-mutilating behavior.
  • November 2020 – Neuralink severs ties with UC Davis on November 11. Neuralink then moves seven of the remaining monkeys to its facility in Fremont, California. Beckham said that records show 15 of the 23 monkeys used in the research died or were euthanized at UC Davis. The final monkey’s situation is unclear, but it is possible the animal was reassigned to a different project at UC Davis, Beckham said.
  • April 2021 – Neuralink releases a YouTube video of “Pager the Monkey” allegedly playing video games with a wireless neural interface. The video features a nine-year-old Macaque named Pager playing “MindPong” while utilizing a Neuralink device.
  • May 2021 – PCRM sues the University of California Davis under the California Public Records Act (CPRA) for not releasing records in September 2020. Before the suit reaches a judicial decision, Counsel for the University of California agrees to release 700 pages of information.
  • October 2021 – University of California’s General Counsel turns over files including animal testing records and veterinarian reports to PCRM. More than 700 pages of records are turned over.
  • February 2022 – PCRM files a separate complaint with the U.S. Department of Agriculture that alleges the information the organization has already received reveals evidence of violations of Federal Animal Welfare laws.

Moving Forward

Beckham maintains that the main point of the newest filing is to have UC Davis turn over photographs and videos that reveal the inhumane treatment of the animals due to the experiments. There are monkeys convulsing, vomiting, and dying in these labs,” Beckham said. “People want to step in line for the first human trials, and they should see this before they commit to that,” he told Teslarati. Neuralink was set for human trials this year, Musk said last year.

Beckham said that these complaints can take a while to work through the legal system. “In my years of being involved with humane testing litigation, I know that these things can take some time. Maybe up to a year,” he said. “It also depends how much they want to fight back.”

Neuralink did not immediately respond to our requests for comment.

Beckham’s full letter to the USDA is available below.

2022-02-10 PCRM USDA Complaint Re UC Davis and Neuralink (No Exhibits) by Joey Klender on Scribd

Advertisement

I’d love to hear from you! If you have any comments, concerns, or questions, please email me at joey@teslarati.com. You can also reach me on Twitter @KlenderJoey, or if you have news tips, you can email us at tips@teslarati.com.

Joey has been a journalist covering electric mobility at TESLARATI since August 2019. In his spare time, Joey is playing golf, watching MMA, or cheering on any of his favorite sports teams, including the Baltimore Ravens and Orioles, Miami Heat, Washington Capitals, and Penn State Nittany Lions. You can get in touch with joey at joey@teslarati.com. He is also on X @KlenderJoey. If you're looking for great Tesla accessories, check out shop.teslarati.com

Advertisement
Comments

Elon Musk

Trump’s invite for Elon just reshuffled Tesla’s big Signature Delivery Event

Tesla rescheduled its final Model S farewell to May 20 after Musk joined Trump in China.

Published

on

By

Tesla has rescheduled its Model S and Model X Signature Edition delivery event to Wednesday, May 20, 2026, after abruptly calling off the original May 12 celebration. The event will take place at Tesla’s factory at 45500 Fremont Boulevard in Fremont, California, the same location where the Model S first rolled off the line in 2012. Invitees received a follow-up email asking them to reconfirm attendance and download a new QR code ticket, with Tesla noting that all travel and accommodation expenses remain the buyer’s responsibility.

The reason behind the original cancellation came into focus the same day it was announced. President Trump invited Elon Musk, Apple’s Tim Cook, BlackRock’s Larry Fink, Boeing’s Kelly Ortberg, and executives from Goldman Sachs, Blackstone, Citigroup, and Meta to join his trip to China this week for a summit with President Xi Jinping. The agenda covers trade, artificial intelligence, export controls, Taiwan, and the Iran war, following weeks of escalating friction between Washington and Beijing over AI technology, sanctions, and rare earth exports. Trump wrote on Truth Social, “I am very much looking forward to my trip to China, an amazing Country, with a Leader, President Xi, respected by all.”

Tesla launches 200mph Model S “Gold” Signature in invite-only purchase

The vehicles at the center of all this are the last Model S and Model X units Tesla will ever build. Priced at $159,420 each, the 250 Model S and 100 Model X Signature Edition units come finished in Garnet Red with a one-year no-resale agreement, giving Tesla right of first refusal if the owner decides to sell. As Teslarati reported, the Model S defined Tesla’s early identity as a serious luxury automaker, and the Fremont factory line that built it is now being converted to manufacture Optimus humanoid robots.

Advertisement

Musk’s inclusion in the China delegation drew attention given his very public relationship with Trump, and the invitation signals the two have moved past and past grievances. Trump originally brought Musk on to lead the Department of Government Efficiency following his inauguration, and despite a sharp public dispute in mid-2025, the two have appeared together repeatedly in recent months. A seat on the China trip, the most diplomatically consequential visit of Trump’s current term, puts Musk back at the table on U.S. economic policy at a moment when Tesla’s China revenue remains one of the company’s most important financial pillars.

Continue Reading

News

Tesla launches its solution to rare but relevant Supercharger problem

Published

on

tesla supercharger
Credit: Tesla

Tesla has launched a new solution to a rare but relevant Supercharger problem with a new Virtual Waitlist, a remedy that will solve sequencing confusion when there is a line to charge at one of the company’s locations.

Teslarati reported on what we called the Virtual Queue last month. In rare occurrences, there were physical altercations at Superchargers when someone might have cut in line to charge. Tesla started to develop some sort of system that would resolve this issue, and now it is finally rolling it out.

Tesla launches solution to end Supercharger fights once and for all

It will start with a Pilot Program, and Tesla is calling it the ‘Waitlist.’

Advertisement

Announced on May 11 on the official TeslaCharging X account, the pilot program is currently active at sites in Los Gatos, Mountain View, and San Francisco in California, as well as San Jose, CA, and the Bronx, NY (East Gun Hill Road). Drivers are encouraged to share feedback directly through the Tesla app to refine the system before a potential broader rollout.

Advertisement

Tesla released the video above to showcase the feature, which automatically joins the waitlist when your vehicle has the Supercharger with the wait as the destination in the navigation. There is also a notification that lets you know your place in line.

In this specific example, the video shows that the wait is less than five minutes, and that there are two cars ahead of the one in the video:

Credit: Tesla

Having a wait at a Supercharger is relatively rare, but it does happen. It is even more frequent now that there are more EVs allowed to use the Supercharger Network. Those non-Tesla EVs can also join the queue, as Tesla added in its social media release of the pilot program that they can join the waitlist using the Tesla app.

The release of this program should help alleviate the rare risk of incidents at Superchargers. Tesla will expand this program as it sees fit, and it gathers valuable data and reviews from users.

Advertisement
Continue Reading

Investor's Corner

Tesla Optimus is already benefiting investors, top Wall Street firm says

Piper Sandler has updated its detailed valuation model for Tesla (NASDAQ: TSLA), concluding that at recent share prices around $400–$420, investors are essentially acquiring the company’s ambitious Optimus humanoid robot project at no extra cost.

Published

on

Credit: Tesla China

Tesla Optimus is already benefiting investors from a fiscal standpoint, at least that is what Alexander Potter at Piper Sandler, a top Wall Street firm covering the company, says.

Piper Sandler has updated its detailed valuation model for Tesla (NASDAQ: TSLA), concluding that at recent share prices around $400–$420, investors are essentially acquiring the company’s ambitious Optimus humanoid robot project at no extra cost.

Analyst Alexander Potter, in the firm’s latest “Definitive Guide to Investing in Tesla,” built a comprehensive framework covering 17 separate product lines.

This granular approach values Tesla’s core businesses—including electric vehicles, energy storage, Full Self-Driving (FSD) software, in-house insurance, Supercharging network, and a standalone robotaxi operation—at approximately $400 per share, without assigning any value to Optimus or related inference-as-a-service opportunities.

Advertisement

“At $400/share, we think investors can buy Optimus for ‘free,’” Potter stated in the note. Piper Sandler maintained its Overweight rating on Tesla shares and a $500 price target, which implicitly attributes roughly $100 per share to the robot-related businesses— a figure the analyst views as potentially conservative.

The updated model incorporates elements often overlooked by other sell-side analysts, such as detailed forecasts for Tesla’s insurance operations, Supercharger revenue, and a distinct valuation for the robotaxi business separate from FSD software licensing. It also accounts for Tesla’s 2025 CEO compensation plan for the first time.

Potter acknowledged that his estimates for 2026 and 2027 fall below Wall Street consensus, citing factors like declining deliveries from certain discontinued models and reduced regulatory credit income.

However, he expressed limited concern, noting that traditional vehicle delivery metrics are expected to matter less over time as FSD subscriber growth and robotaxi deployment metrics gain prominence. On Optimus specifically, Potter suggested the humanoid robot program, combined with inference services, “arguably will be worth more than Tesla’s other businesses combined,” though the firm has not yet produced formal long-term forecasts for these segments.

Advertisement

Elon Musk reveals shocking Tesla Optimus patent detail

Tesla shares have traded near the $400 range in recent sessions, reflecting ongoing investor focus on the company’s autonomous driving progress and expansion into robotics and AI. The Optimus project remains in early development stages, with Tesla aiming to deploy the robots initially for internal factory tasks before broader commercial applications.

This Piper Sandler analysis highlights the growing emphasis among some investors and analysts on Tesla’s long-term technology platform potential beyond its current automotive and energy businesses.

As with any forward-looking valuation, outcomes will depend on execution timelines, technological breakthroughs, regulatory approvals for autonomous systems, and market adoption of humanoid robotics—areas that carry significant uncertainty and execution risk.

Advertisement

The note underscores a common theme in Tesla coverage: differing views on how to quantify emerging high-growth opportunities like robotics within the company’s overall enterprise value. Investors are advised to consider their own risk tolerance and conduct thorough due diligence regarding these speculative elements.

Continue Reading